Olema Pharmaceuticals, Inc. (OLMA) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Olema Pharmaceuticals, Inc. (OLMA) posted $0 in revenue for fiscal 2025, with a net loss of $162.45M, per its SEC filings.
Data last refreshed September 3, 2026 from SEC filings · how we compute this
The analyst's take on Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. has grown revenue from — to $0 over the last 7 fiscal years.
It carries about $3.00M of total debt.
It clears 1 of 4 deterministic health checks. The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Olema Pharmaceuticals, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
See a claim about Olema Pharmaceuticals, Inc.? Check it against the filing
Open the full tool →Paste a headline number you saw about OLMA — a press-release figure, a tweet, another tool’s number — and see the filed SEC number side-by-side with its source. Free, no account.
Olema Pharmaceuticals, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — |
| Net income | $-4.32M | $-22.12M | $-71.10M | $-104.79M | $-96.66M | $-129.47M | $-162.45M |
| Net margin | — | — | — | — | — | — | — |
Source: Olema Pharmaceuticals, Inc. SEC filings (10-K).
Olema Pharmaceuticals, Inc. financial health: 1 of 4 checks passed
- ✗Profitable every year (last 5)
- ✓More cash than total debt (cash 505.4M vs debt 3M)
- ✗Positive operating cash flow (last 5 yrs)
- ✗Share count falling over 5 yrs (buybacks) (39.3M → 81.4M shares)
Checks computed deterministically from filed annual statements — no AI judgement.
Olema Pharmaceuticals, Inc.: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 104.5% over 4 years (39.8M → 81.4M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $3M of debt while last year's operating cash flow was negative ($-146.7M).
Explore 7 years of Olema Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a $24.99/month plan to track OLMA in your portfolio →
Olema Pharmaceuticals, Inc. financial history
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals, Inc. — frequently asked questions
What is Olema Pharmaceuticals, Inc.'s revenue?
Olema Pharmaceuticals, Inc. (OLMA) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Olema Pharmaceuticals, Inc. profitable?
No — OLMA reported a net loss of $-162.45M in fiscal 2025.
How much debt does Olema Pharmaceuticals, Inc. have?
As of fiscal year 2025, OLMA carried roughly $3.00M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Olema Pharmaceuticals, Inc.'s market cap?
Olema Pharmaceuticals, Inc. (OLMA) has a market capitalization of about $835.04M, based on the latest data in our nightly-refreshed cache.
When does Olema Pharmaceuticals, Inc.'s fiscal year end?
OLMA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Olema Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.